Back to top

zacks-consensus-estimate: Archive

Zacks Equity Research

Why Is Central Garden (CENT) Down 5.6% Since Last Earnings Report?

Central Garden (CENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Agilent (A) Down 12% Since Last Earnings Report?

Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Woodward (WWD) Up 7.7% Since Last Earnings Report: Can It Continue?

Woodward (WWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Semtech (SMTC) Up 5.8% Since Last Earnings Report: Can It Continue?

Semtech (SMTC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Keysight (KEYS) Up 5% Since Last Earnings Report: Can It Continue?

Keysight (KEYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Zoom (ZM) Up 1% Since Last Earnings Report: Can It Continue?

Zoom (ZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Wall Street Analysts Think AvePoint (AVPT) Could Surge 46.84%: Read This Before Placing a Bet

The consensus price target hints at a 46.8% upside potential for AvePoint (AVPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know

The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Pinnacle Financial (PNFP) Upgraded to Buy: What Does It Mean for the Stock?

Pinnacle Financial (PNFP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.